Debate: Are Hydroxylase Inhibitors Stabilizers a Viable Alternative to Erythropoiesis-Stimulating Agents in the Management of Anemia in CKD? CON

What Is the Role of Daprodustat in Treatment of Anemia in People on Maintenance Dialysis?

“…In dialysis patients in particular, there is concern about adverse effects on diabetic retinopathy, pulmonary hypertension, cyst progression, and thrombosis. 10 Given this, and the fact that we have treatments that we know a lot about and have grown comfortable using, I would not be an early adopter and either prescribe or take a HIF-PHI unless a very high ESA dose was needed to achieve a reasonable hemoglobin level or one could not be achieved at all with an injectable ESA. Under these circumstances, a trial of daprodustat could be considered, stopping it if the desired outcome is not achieved in a few months.…”